EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY-NC 4.0

Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial

Yoshifumi Takahashi iD, Hiroyuki Fujiwara iD, Kouji Yamamoto iD, Masashi Takano iD, Morikazu Miyamoto iD, Kosei Hasegawa iD, Maiko Miwa iD, Toyomi Satoh iD, Hiroya Itagaki iD, Takashi Hirakawa iD, Mayuyo Mori-Uchino iD, Tomonori Nagai iD und 7 weitere

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e37 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Yoshifumi Takahashi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan. ytakahashi@jichi.ac.jp. Hauptthemen laut MEDLINE: Pulmonary Embolism, Genital Neoplasms, Female, Venous Thromboembolism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: In Japan, perioperative prophylaxis of pulmonary embolism (PE) in gynecologic cancer patients with preoperative asymptomatic venous thromboembolism (VTE) has not been well established yet. The GOTIC-VTE trial was a prospective, multi-center, single-arm clinical trial to investigate the prevention of postoperative symptomatic PE onset by seamless anticoagulant therapy from the preoperative period to 4 weeks after surgery instead of using intermittent pneumatic compression. METHODS: Anticoagulant therapy was started immediately after asymptomatic VTE diagnosis and stopped preoperatively according to the rules of each institution. Unfractionated heparin administration was resumed within 12 hours postoperatively, and this was followed by the switch to low-molecular-weight heparin and subsequently, edoxaban; this cycle was continued for 28 days. Primary outcome was the occurrence of symptomatic PE in 28 days postoperatively. Secondary outcomes were the incidence of VTE-related events in 28 days and 6 months postoperatively and protocol-related adverse events. RESULTS: Between February 2018 and September 2020, 99 patients were enrolled; of these, 82 patients were assessed as the full analysis set, including 58 for ovarian cancer, fallopian tube, or peritoneal cancer; 21 for endometrial cancer; and 3 for cervical cancer. No symptomatic PE was observed within 28 days postoperatively; two patients had bleeding events (major bleeding and clinically relevant nonmajor bleeding) and three had grade 3 adverse events (increased alanine transaminase, aspartate aminotransferase, or gamma-glutamyl transferase). CONCLUSION: The multifaceted perioperative management for gynecologic malignancies with asymptomatic VTE effectively prevented postoperative symptomatic PE. TRIAL REGISTRATION: JRCT Identifier: jRCTs031180124.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismGenital Neoplasms, FemaleVenous ThromboembolismHumansFemaleMiddle AgedAgedProspective StudiesPostoperative ComplicationsHeparin, Low-Molecular-WeightAnticoagulantsAdultPyridinesThiazolesHeparinJapan

Stichwörter der Autor:innen

AnticoagulantsGynecologic NeoplasmsGynecologic SurgeryPulmonary EmbolismVenous Thromboembolism

Substanzen

Heparin, Low-Molecular-WeightAnticoagulantsedoxabanPyridinesThiazolesHeparin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan. ytakahashi@jichi.ac.jp.
  • Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan.
  • Department of Biostatistics, School of Medicine, Yokohama City University, Kanagawa, Japan.
  • Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan.
  • Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

ORCID-Profile: Yoshifumi Takahashi, Hiroyuki Fujiwara, Kouji Yamamoto, Masashi Takano, Morikazu Miyamoto, Kosei Hasegawa, Maiko Miwa, Toyomi Satoh, Hiroya Itagaki, Takashi Hirakawa, Mayuyo Mori-Uchino, Tomonori Nagai, Yoshinobu Hamada, Soichi Yamashita, Hiroko Yano, Tomoyasu Kato, Keiichi Fujiwara, Mitsuaki Suzuki

Förderung

  • Daiichi-Sankyo

Zitieren

APA

Takahashi, Y., Fujiwara, H., Yamamoto, K., Takano, M., Miyamoto, M., Hasegawa, K., Miwa, M., Satoh, T., Itagaki, H., Hirakawa, T., Mori-Uchino, M., Nagai, T., Hamada, Y., Yamashita, S., Yano, H., Kato, T., Fujiwara, K., Suzuki, M., & GOTIC-VTE Trial Investigators (2024). Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e37

Vancouver

Takahashi Y, Fujiwara H, Yamamoto K, Takano M, Miyamoto M, Hasegawa K, et al. Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e37

BibTeX
@article{Takahashi2024,
  author = {Takahashi, Yoshifumi and Fujiwara, Hiroyuki and Yamamoto, Kouji and Takano, Masashi and Miyamoto, Morikazu and Hasegawa, Kosei and Miwa, Maiko and Satoh, Toyomi and Itagaki, Hiroya and Hirakawa, Takashi and Mori-Uchino, Mayuyo and Nagai, Tomonori and Hamada, Yoshinobu and Yamashita, Soichi and Yano, Hiroko and Kato, Tomoyasu and Fujiwara, Keiichi and Suzuki, Mitsuaki and GOTIC-VTE Trial Investigators, GOTIC-VTE Trial Investigators},
  title = {Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e37}
}
Kostenlos starten →